American Kidney Fund Launches National Kidney Health Equity Media Campaign
25 Abril 2024 - 8:01AM
As part of its longstanding commitment to kidney health equity, the
American Kidney Fund (AKF) has launched a national media campaign
aimed at bringing greater awareness of kidney disease within Black
and Hispanic/Latino communities, the two groups most
disproportionately affected by kidney failure in the United States.
A central piece of AKF’s Kidney Health for All™ program, this
yearlong campaign focuses on prevention and disease management and
will include national TV, streaming and radio PSAs, digital
advertising, video in primary care doctor’s offices, and ads on
billboards and public transit in metropolitan areas with high rates
of kidney disease. The English and Spanish language PSAs feature
Dr. Silas Norman, chair of AKF’s Board of Trustees and Co-Medical
Director, Kidney and Pancreas Transplantation at the University of
Michigan, and Dr. Pablo Garcia, a nephrologist and transplant
nephrologist at the University of New Mexico. Garcia is also
Director of the Living Donor Program and Director of the Outpatient
Nephrology Clinics at the University of New Mexico.
In the U.S., the prevalence of kidney failure among Black people
is more than four times that of white people, while the prevalence
of kidney failure in Hispanic or Latino people is more than twice
that of white people, according to the U.S. Renal Data System.
“Our message is clear: ‘We don’t just believe in Kidney Health
for All – we work to achieve it,’” said LaVarne A. Burton, AKF
President and CEO. “Through these awareness efforts, we hope to
educate Americans, particularly those in communities where rates of
end-stage kidney disease are high, that dialysis is not evitable.
We are urging people to see their health care provider regularly
and get their kidneys checked, so that they are empowered to
prevent or slow the progression of kidney disease.”
AKF’s health equity initiative centers around four pillars:
- Preventing and slowing the progression of kidney disease
- Increasing diversity in clinical trials to reflect the
populations the medications will treat
- Increasing awareness and utilization of home dialysis, which
can result in better outcomes, as an available treatment
option
- Increasing access and removing barriers to kidney
transplantation among people of color
PSAs may be viewed on AKF’s Kidney Health for All website
(KidneyHealthForAll.org) and in Spanish at
Saludrenalparatodos.org.
Kidney Health for All is supported by Presenting Sponsors
Boehringer Ingelheim and Eli Lilly and Company, Travere
Therapeutics, Inc., and Vertex Pharmaceuticals Incorporated;
Leadership Sponsors AstraZeneca and Merck; and Equity Sponsors
Otsuka America Pharmaceutical, Inc. and Sanofi.
###
About the American Kidney Fund
The American Kidney Fund (AKF) fights kidney disease on all
fronts as the nonprofit with the greatest direct impact on people
with kidney disease. AKF works on behalf of 1 in 7 Americans living
with kidney disease, and the millions more at risk, with an
unmatched scope of programs that support people wherever they are
in their fight against kidney disease—from prevention through
transplant. AKF fights for kidney health for all through programs
that address early detection, disease management, financial
assistance, clinical research, innovation and advocacy. AKF is one
of the nation’s top-rated nonprofits, investing 97 cents of every
donated dollar in programs, and holds the highest 4-Star rating
from Charity Navigator for 21 consecutive years and the Platinum
Seal of Transparency from Candid, formerly known as GuideStar.
For more information, please visit KidneyFund.org, or connect
with us on Facebook, Twitter, Instagram and LinkedIn.
Nancy Gregory
American Kidney Fund
(240) 292-7077
ngregory@kidneyfund.org